- Home
- LEO vs IOVA Comparison
LEO vs IOVA Comparison
Compare LEO & IOVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LEO
- IOVA
- Stock Information
- Founded
- LEO 1987
- IOVA 2007
- Country
- LEO United States
- IOVA United States
- Employees
- LEO N/A
- IOVA N/A
- Industry
- LEO Trusts Except Educational Religious and Charitable
- IOVA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- LEO Finance
- IOVA Health Care
- Exchange
- LEO Nasdaq
- IOVA Nasdaq
- Market Cap
- LEO N/A
- IOVA 1.0B
- IPO Year
- LEO N/A
- IOVA N/A
- Fundamental
- Price
- LEO $5.83
- IOVA $3.51
- Analyst Decision
- LEO
- IOVA Strong Buy
- Analyst Count
- LEO 0
- IOVA 9
- Target Price
- LEO N/A
- IOVA $18.22
- AVG Volume (30 Days)
- LEO 200.2K
- IOVA 10.2M
- Earning Date
- LEO 01-01-0001
- IOVA 05-08-2025
- Dividend Yield
- LEO 4.01%
- IOVA N/A
- EPS Growth
- LEO N/A
- IOVA N/A
- EPS
- LEO 0.04
- IOVA N/A
- Revenue
- LEO N/A
- IOVA $164,070,000.00
- Revenue This Year
- LEO N/A
- IOVA $182.20
- Revenue Next Year
- LEO N/A
- IOVA $62.10
- P/E Ratio
- LEO $152.00
- IOVA N/A
- Revenue Growth
- LEO N/A
- IOVA 13698.99
- 52 Week Low
- LEO $4.98
- IOVA $2.70
- 52 Week High
- LEO $6.50
- IOVA $14.23
- Technical
- Relative Strength Index (RSI)
- LEO 43.70
- IOVA 51.94
- Support Level
- LEO $5.67
- IOVA $2.89
- Resistance Level
- LEO $5.88
- IOVA $3.43
- Average True Range (ATR)
- LEO 0.12
- IOVA 0.32
- MACD
- LEO 0.01
- IOVA 0.09
- Stochastic Oscillator
- LEO 50.00
- IOVA 86.17
About IOVA Iovance Biotherapeutics Inc.
Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. its objective is to be the leader in innovating, developing, and delivering tumor-infiltrating lymphocyte, or TIL, therapies for patients with solid tumor cancers.